Inovio, Transgene and ChronTech Collaborate for HCV Vaccine

20 April 2011 (Last Updated April 20th, 2011 18:30)

Inovio Pharmaceuticals has signed an agreement with Transgene and ChronTech Pharma to jointly evaluate a therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) in a phase I trial. The clinical study, which will start later this year, is set to use ChronTech's ChronVa

Inovio Pharmaceuticals has signed an agreement with Transgene and ChronTech Pharma to jointly evaluate a therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) in a phase I trial.

The clinical study, which will start later this year, is set to use ChronTech's ChronVac-C plasmid DNA vaccine delivered in vivo electroporation using Inovio's Medpulser DNA Delivery System (DDS) as the initial vaccination, followed by Transgene's therapeutic vaccine TG4040, a modified vaccinia Ankara (MVA).

Inovio's MedPulser DDS device delivers electrical pulses, enhancing cell membrane permeability, cellular uptake of the DNA vaccine and gene expression.

In previous trials the ChronVac-C DNA vaccine and the TG4040 were found to be safe and more immunogenic than those observed when they were injected separately.

The ChronVac-C plasmid DNA vaccine delivered by in vivo electroporation using the Medpulser was reported to be safe and generated antigen-specific immune responses and antiviral effects in a phase I/IIa trial.

Each partner will contribute its products and equally share costs related to the study, which will enroll 12 treatment-naive patients with chronic hepatitis C at a German site.